Halozyme Therapeutics, Inc.
Halozyme Therapeutics develops proprietary enzymes and devices for various treatments. Products include Hylenex recombinant, rilpivirine, cabotegravir, ocrelizumab, XYOSTED, ATRS-1902, Herceptin, Mabthera SC, HYQVIA, DARZALEX, Epinephrine Injection, nivolumab+relatlimab, ANTI-TIM3, ARGX-117, atezolizumab, and others. The company provides treatments for breast cancer, chronic lymphocytic leukemia, primary immunodeficiency disorders, amyloidosis, smoldering myeloma, multiple myeloma, allergic reactions, solid tumors, and severe autoimmune diseases. Halozyme also offers products for adrenal crisis rescue and various other conditions. Founded in 1998, the company is headquartered in San Diego, California.
Overview
Strengths
- Creates economic value: ROIC of 27.5% against a cost of capital (WACC) of 7.5%, a spread of 20.0 percentage points.
- High-quality earnings: over the last 6 years, free cash flow added up to 100% of reported net income.
- Consistent growth: revenue has compounded at 39.2% a year over 5 years, rising every year.
- Shareholder-friendly capital allocation: the share count has shrunk by 4.5% a year over the last three years through buybacks.
- ROIC of 27.5% beats 84% of its 128 Biotechnology peers (median 0.0%).
- EBITDA margin of 63.8% beats 95% of its 128 Biotechnology peers (median 0.0%).
Weaknesses
- Our discounted cash flow target price (57.24 USD) is 53% below the current price.
- Valued at a premium to its Biotechnology peers: P/E 45.7x vs. a median of 19.2x and P/FCF 40.6x vs. a median of 18.8x.
- More expensive than its own history: P/E 45.7x vs. a historical average of 21.8x.
Key Financial Data